CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

Abstract Background The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco, Tracey O’Connor
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2021-05-01
סדרה:	Cardio-Oncology
נושאים:	Anthracycline Breast Cancer Carbonyl Reductase 3 Cardiotoxicity Cardiovascular disease Chemotherapy
גישה מקוונת:	https://doi.org/10.1186/s40959-021-00103-0
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!